BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:925-932. [PMID: 20480515 DOI: 10.1002/ibd.21284] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis. 2013;7:113-119. [PMID: 22464811 DOI: 10.1016/j.crohns.2012.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
2 Ahluwalia JP. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012;96:525-44. [DOI: 10.1016/j.mcna.2012.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ren R, Wang T, Jiang N, Liu T, Du Y, Li C, Zhang L, Fu F. Protective effects of Danshensu on liver injury induced by omethoate in rats. Toxicology Mechanisms and Methods 2010;20:510-4. [DOI: 10.3109/15376516.2010.514963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
5 Gordon JA, Jakhete N, Borum ML. Improving care for inflammatory bowel disease patients infected with hepatitis B virus. Inflamm Bowel Dis. 2013;19:E53-E54. [PMID: 23354318 DOI: 10.1097/mib.0b013e318280eb1f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
7 Crawford NW, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2011;11:87. [PMID: 21798078 DOI: 10.1186/1471-230x-11-87] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
8 Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1379-1385. [PMID: 22530631 DOI: 10.1111/j.1365-2036.2012.05110.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
9 Cossio-gil Y, Martínez-gómez X, Campins-martí M, Rodrigo-pendás JÁ, Borruel-sainz N, Rodríguez-frías F, Casellas-jordà F. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination: Hepatitis B vaccine in bowel disease. J Gastroenterol Hepatol 2015;30:92-8. [DOI: 10.1111/jgh.12712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
10 Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013;10:277-85. [PMID: 23419290 DOI: 10.1038/nrgastro.2013.28] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
11 Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol. 2012;107:133-138. [PMID: 21876562 DOI: 10.1038/ajg.2011.295] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
12 Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1655-1667. [PMID: 24874461 DOI: 10.1097/mib.0000000000000065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
13 Cekic C, Aslan F, Kirci A, Gümüs ZZ, Arabul M, Yüksel ES, Vatansever S, Yurtsever SG, Alper E, Ünsal B. Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease. Medicine (Baltimore) 2015;94:e940. [PMID: 26039133 DOI: 10.1097/MD.0000000000000940] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
14 Chan HC, Wong VW, Wong GL, Tang W, Wu JC, Ng SC. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol. 2016;16:100. [PMID: 27549153 DOI: 10.1186/s12876-016-0516-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9691-9698 [PMID: 25110408 DOI: 10.3748/wjg.v20.i29.9691] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
16 Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30:1591-1595. [PMID: 25967740 DOI: 10.1111/jgh.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
17 Yokoyama Y, Fukunaga K, Kamikozuru K, Sato T, Kawai M, Nogami K, Nagase K, Nakamura M, Immured M, Hida N, Nakamura S. Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. Cytotherapy 2014;16:821-5. [PMID: 24713332 DOI: 10.1016/j.jcyt.2014.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
18 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2142-50. [PMID: 25072501 DOI: 10.1097/MIB.0000000000000126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
20 Cao Y, Zhao D, Xu AT, Shen J, Ran ZH. Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease. Chin Med J (Engl) 2015;128:835-8. [PMID: 25758282 DOI: 10.4103/0366-6999.152683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
22 Cordero-Coma M, Salazar-Méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues. Expert Opin Drug Saf 2015;14:1353-71. [PMID: 26118392 DOI: 10.1517/14740338.2015.1061992] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
24 Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol 2021; 13(12): 1956-1967 [DOI: 10.4254/wjh.v13.i12.1956] [Reference Citation Analysis]
25 Cunha IS, Silva TCD, Malluta ÉF, Scolaro BL, Velho PS, Stall J. SEROCONVERSION ANALYSIS AFTER HABITUAL HEPATITIS B VACCINATION SCHEME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Arq Gastroenterol 2020;57:69-73. [PMID: 32294738 DOI: 10.1590/S0004-2803.202000000-12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Coukos J, Farraye FA. Update on Vaccinating the Patient With Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2018;16:548-60. [PMID: 30293209 DOI: 10.1007/s11938-018-0200-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Louis E, Baumgart DC, Ghosh S, Gomollón F, Hanauer S, Hart A, Irving P. What changes in inflammatory bowel disease management can be implemented today? Journal of Crohn's and Colitis 2012;6:S260-7. [DOI: 10.1016/s1873-9946(12)60506-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1460-1466. [PMID: 23034605 DOI: 10.1038/ajg.2012.79] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 9.0] [Reference Citation Analysis]
29 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). Intest Res 2018;16:178-93. [PMID: 29743831 DOI: 10.5217/ir.2018.16.2.178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
30 Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol. 2011;46:855-861. [PMID: 21506630 DOI: 10.3109/00365521.2011.574734] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
31 Mukhopadhyay A, Maulik U. Network-based study reveals potential infection pathways of hepatitis-C leading to various diseases. PLoS One 2014;9:e94029. [PMID: 24743187 DOI: 10.1371/journal.pone.0094029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
32 Sánchez-Tembleque MD, Corella C, Pérez-Calle JL. Vaccines and recommendations for their use in inflammatory bowel disease. World J Gastroenterol 2013; 19(9): 1354-1358 [PMID: 23538680 DOI: 10.3748/wjg.v19.i9.1354] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
33 Watts A, Bennett WE, Molleston JP, Gupta SK, Croffie JM, Waseem S, McFerron BA, Steiner SJ, Kumar S, Vanderpool CP, Hon EC, Bozic MA, Subbarao GC, Pfefferkorn MD. Incidence of Low Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017;65:551-4. [PMID: 28333769 DOI: 10.1097/MPG.0000000000001580] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
34 Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366 [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
35 King LK, Lee A, Anandacoomarasamy A. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. Intern Med J 2012;42:523-31. [PMID: 21790927 DOI: 10.1111/j.1445-5994.2011.02569.x] [Reference Citation Analysis]
36 Manser CN, Maillard MH, Rogler G, Schreiner P, Rieder F, Bühler S; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Vaccination in Patients with Inflammatory Bowel Diseases. Digestion 2020;101 Suppl 1:58-68. [PMID: 31968344 DOI: 10.1159/000503253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
37 Abreu NA, Nagalingam NA, Song Y, Roediger FC, Pletcher SD, Goldberg AN, Lynch SV. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med 2012;4:151ra124. [PMID: 22972842 DOI: 10.1126/scitranslmed.3003783] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 28.7] [Reference Citation Analysis]
38 Urganci N, Kalyoncu D. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:412-415. [PMID: 23841120 DOI: 10.1097/mpg.0b013e31827dd87d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
39 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [PMID: 34904028 DOI: 10.4254/wjh.v13.i11.1534] [Reference Citation Analysis]
40 Kim K, Ki S. Nrf2. Liver Pathophysiology. Elsevier; 2017. pp. 355-74. [DOI: 10.1016/b978-0-12-804274-8.00028-x] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:554-8. [PMID: 23380936 DOI: 10.1097/MIB.0b013e31827febe9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
42 Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7(3): 387-396 [PMID: 27602239 DOI: 10.4292/wjgpt.v7.i3.387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
43 Selmi C, De Santis M, Gershwin ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther 2011;13:226. [PMID: 21722332 DOI: 10.1186/ar3319] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
44 Shakya N, Vedi S, Liang C, Agrawal B, Tyrrell DL, Kumar R. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. Bioorg Med Chem Lett 2012;22:6475-80. [PMID: 22985854 DOI: 10.1016/j.bmcl.2012.08.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Shin SM, Yang JH, Ki SH. Role of the Nrf2-ARE pathway in liver diseases. Oxid Med Cell Longev. 2013;2013:763257. [PMID: 23766860 DOI: 10.1155/2013/763257] [Cited by in Crossref: 99] [Cited by in F6Publishing: 109] [Article Influence: 11.0] [Reference Citation Analysis]
46 Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Guéant JL, Bronowicki JP, Peyrin-Biroulet L. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2015;27:877-81. [PMID: 26121376 DOI: 10.1097/MEG.0000000000000370] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
47 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
48 Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50:1700-1711. [PMID: 21690185 DOI: 10.1093/rheumatology/ker190] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 8.5] [Reference Citation Analysis]